Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 6/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.48 |
| ▸ | HRH1 | P35367 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | THPO | P40225 | 2/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499960 | 1.00 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| SCHEMBL2805296 | 1.00 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| Cadaverine Tartrate SCHEMBL20898277 | 0.91 | POLB (0.45) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| Cadaverine Tartrate SCHEMBL20898278 | 0.91 | POLB (0.45) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| Cadaverine Tartrate SCHEMBL8638485 | 0.91 | POLB (0.45) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| Cadaverine Tartrate SCHEMBL20898382 | 0.91 | POLB (0.45) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| SCHEMBL9533118 | 0.89 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| SCHEMBL12064971 | 0.86 | SLC6A2 (0.48) | SLC6A4SLC6A2SLC6A3HRH1KCNH2 | |
| SCHEMBL20898695 | 0.86 | POLB (0.43) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B | |
| SCHEMBL15467772 | 0.86 | POLB (0.43) | SLC6A4SLC6A2SLC6A3CHRM2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116556-B | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-111116556-A | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-113072486-B | Amino alcohol-boron-binaphthol complex and preparation method of optically active amino alcohol derivative using same | 分子与物质株式会社 | 2024-10-11 | — | — | CN | disclosed |
| CN-117164419-A | Chiral synthesis method of bestatin intermediate | 江苏联环药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| CN-111116556-B | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-111116556-B | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-111116556-B | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-111116556-A | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116556-A | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| CN-111116556-A | Preparation method of (R) -2- [ (4-chlorphenyl) (4-piperidinyloxy) methyl ] pyridine | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20100168433-A1 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| EP-2167488-A2 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | Hanmi Pharm. Co., Ltd. (KR) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008153289-A2 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HANMI PHARM. CO., LTD. (KR) | 2008-12-18 | — | — | WO | disclosed |
| US-7282589-B2 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2007-10-16 | — | — | US | disclosed |
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. | 2004-11-04 | — | — | US | disclosed |
| US-6780877-B2 | ANTIHISTAMINIC ACTIVITY, ANTI-ALLERGIC ACTIVITY | UBE INDUSTRIES, LTD. (JP) | 2004-08-24 | — | — | US | disclosed |
| EP-0949260-B1 | ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-20020026054-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | UBE INDUSTRIES, LTD. | 2002-02-28 | — | — | US | disclosed |
| US-6307052-B1 | Acid-addition salts of optically active piperidine compound and process for producing the same | UBE INDUSTRIES, LTD. (JP) | 2001-10-23 | — | — | US | disclosed |
| EP-0949260-A1 | ACID-ADDITION SALTS OF OPTICALLY ACTIVE PIPERIDINE COMPOUND AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168433-A1 | PROCESS FOR PREPARING BEPOTASTINE AND INTERMEDIATES USED THEREIN | HRH4, HRH2, HRH1 | SLC6A4 2765/4885SLC6A2 3741/4885SLC6A3 3930/4885 |
| US-20020026054-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | CMA1, HRH1, HRH2 | SLC6A4 2028/4885SLC6A2 3209/4885SLC6A3 3661/4885 |
| US-20040220226-A1 | Acid addition salt of optically active piperidine compound and process for preparing the same | DCTPP1, SSRP1, ITPA | SLC6A4 170/4885SLC6A2 828/4885SLC6A3 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.